Jobs / United States / Eikon Therapeutics INC
Senior Director, Translational Medicine
Eikon Therapeutics INC · 🇺🇸 Jersey City, NJ; Millbrae, CA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 13 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 1 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Eikon Therapeutics INC
The US Department of Labor certified 13 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 1 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Eikon Therapeutics INC →
About the role
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells, thereby unlocking otherwise intractable classes of proteins as drug targets. Position As Senior Director of Translational Medicine, you will play a vital role in driving biomarker research for our innovative clinical pipeline. You will lead cross-functional teams in the development of biomarker strategies, selection and validation of biomarker assays, and analysis and interpretation of biomarker data to support the advancement of our clinical programs. About You You are a strategic thinker with strong scientific acumen, have proven leadership and influence skills, and demonstrate a deep understanding of the impact of translational medicine in drug development. You bring extensive expertise in the classes of biomarkers that influence clinical development, an understanding of fit-for-purpose assay validation, and ability to perform data analysis through to impactful conclusion and interpretation. This role requires onsite presence at least 3 days per week (or more as business needs require) in our Jersey City, NJ or Millbrae, CA offices to ensure effective communication, operational excellence, and high-performance execution of clinical trials. What You’ll Do • Lead one or more cross-functional Biomarker Subteam(s) to develop and implement a comprehensive biomarker strategy aligned with oncology clinical program goals. • Establish and maintain strong collaborations with research, clinical development, clinical pharmacology, biostatistics, regulatory affairs, data management, clinical operations, and commercial teams. • Provide strategic input into preclinical and clinical development plans, ensuring seamless translation of scientific findings. • Identify and champion novel translational approaches and technologies to enhance drug development. • Lead the identification, validation, and implementation of relevant biomarkers (pharmacodynamic, predictive, prognostic, mechanism of action, safety, resistance) to deliver key trial objectives such as patient selection, dose optimization, and therapeutic response monitoring. • Author biomarker sections of clinical protocols and oversee their execution. • Ensure the rigorous, fit-for-purpose analytical validation of selected biomarker assays. • Contribute to the scientific community through publications, presentations, and active knowledge-sharing. • Contribute to health authority interactions and submissions, including INDs, NDAs/BLAs, and CDx filings. • Ensure all translational medicine activities are conducted in compliance with GCP, regulatory guidelines, and ethical standards. Qualifications • PhD and postdoctoral training in the area of oncology, immunology, or a related field with minimum of 10 years of clinical biomarker development experience in a drug development setting. • Experience translating disease biology and preclinical pharmacology into clinical biomarker strategies that impact the clinical development of oncology therapeutics. • Outstanding strategic and critical thinking skills, with a track record of proactive innovation, scientific excellence, and demonstrated ability to analyze and interpret complex biomarker data. • Ability to work as part of a collaborative team and clearly communicate the impact of biomarker plans and outcomes on clinical development, both orally and in writing. • Expertis